Rice lab’s injectable gel feeds steady dose of drugs to tumor cells
An immunotherapy drug embedded in a slow-release hydrogel invented at Rice University in collaboration with the University of Texas Health Science Center at Houston (UTHealth) appears to be highly effective at killing cancer cells.
STINGel combines a new class of immunotherapy drugs called stimulator of interferon gene (STING) agonists with an injectable hydrogel that releases the drug in a steady dose to activate the immune system to kill cancer cells. It was developed by the Rice lab of chemist and bioengineer Jeffrey Hartgerink and Rice alum Simon Young, an assistant professor of oral and maxillofacial surgery at UTHealth.
In clinical trials, immunotherapy drugs have demonstrated strong cancer-fighting abilities. Research has also found that the drugs are flushed quickly from the body, and current trials require multiple injections.
The new research, which is detailed in Biomaterials, showed that slow-release peptide gels could continuously deliver immunotherapy drugs to tumor sites for long periods of time.
Hartgerink is a pioneer in the development of self-assembling multidomain peptide (MDP) hydrogels, which mimic the body’s extracellular matrix to encourage the growth of cells and vascular systems for tissue repair. The hydrogel is injected as a liquid, turns semisolid inside the body and slowly degrades over time.
The hydrogel in the new study is also welcoming to cells, but when the invaders are cancer cells, they’re in for trouble. Immunotherapy drugs known as cyclic dinucleotides (CDNs) await them inside the gel.
Hartgerink, a professor of chemistry and bioengineering, said the concentration of CDN in the hydrogel is important.
“The normal approach to CDN delivery is simple injection, but this leads to very rapid diffusion of the drug throughout the body and reduces its concentration at the site of the tumor to very low levels,” he said. “Using the same amount of CDN, the STINGel approach allows the concentration of CDN near the tumor to remain much higher for long periods of time.”
STINGel was studied both in lab cultures and in vivo. For the in vivo portion, six groups of 10 rodents each were treated with CDN alone, control collagens alone or with CDN, MDP alone or STINGel (CDN plus MDP). Only one in 10 CDN or collagen plus CDN animals survived 105 days, but six of 10 animals treated with STINGel survived. These also proved resistant to further implantation of cancer cells, meaning their immune systems were trained to successfully identify and destroy both the existing cancer and future occurrence of that cancer, Hartgerink said.
The lab tested more common hydrogels but found that they were unable to provide the same controlled release and also failed to provide an additional benefit over CDN treatment seen in clinical trials. “The MDP hydrogel provides a unique environment for the release of CDN that other gels just can’t match,” Hartgerink said.
“The CDN we used in this study is currently in clinical trials,” he said. “We think that our STINGel approach has the potential to significantly broaden the scope of this powerful immunotherapy drug to a larger range of resistant cancers.”
The Latest on: Cancer immunotherapy
- Dr. Sonpavde on Remaining Questions With Immunotherapy in Bladder Cancer on September 19, 2018 at 12:43 pm
Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses remaining questions with immunotherapy in bladder cancer. PD-1/PD-L1 inhibitors have shown great tolerability a... […]
- Enhancing Cancer Immunotherapy with Artificial Intelligence on September 19, 2018 at 9:45 am
Physicians may soon use artificial intelligence (AI) and medical images to study tumors without a biopsy. The techniques developed to study tumors in this new way are described in the September 1 issu... […]
- NOXXON to Present Clinical Trial Data at Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference ‘Translati... on September 18, 2018 at 11:00 pm
NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that Aram ... […]
- The Cancer Center at BIDMC Opens a Personalized Immunotherapy Cancer Vaccine Facility on September 17, 2018 at 1:51 pm
Newswise — BOSTON – The Cancer Center at Beth Israel Deaconess Medical Center (BIDMC) today announced the opening of the Randi and Brian Schwartz Family Cancer Immunotherapy and Cell Manipulation Faci... […]
- "As quick as you can get:" Toddler cancer free after 10 days of immunotherapy on September 16, 2018 at 6:24 am
SEATTLE, Wash. (KOMO) --Harper Beare is just shy of her second birthday, and almost everything about her is typical two-year-old. But this little girl has spent nearly half her life in and out of hosp... […]
- The cancer patient had exhausted his options. Enter immunotherapy. on September 14, 2018 at 1:03 pm
A year after doctors removed a tumor from Kevin Hill's body, his nightmare seemed to fade. At 26, he was happy, healthy and alive. He would touch the foot-long scar that stretches from his chest to si... […]
- Doctors work to treat cancer with immunotherapy on September 13, 2018 at 9:36 am
(KAIT/NBC) - Doctors said one cancer patient’s result gave them new hope with a new cancer treatments, called ‘Immunotherapy’. In 2017, Ruth Wright learned her breast cancer had spread to her lungs, l... […]
- Cancer Immunotherapy Market Expected to Surpass 101.6 Billion by 2023 with Major Players as Celgene Corporation, Merck & Co and Amgen Inc on September 12, 2018 at 5:01 am
The Global Cancer Immunotherapy Market has been growing impressively and is expected to maintain the same momentum during the forecast period. Market Research Future (MRFR) projects that the global ca... […]
- Three Scientists to Receive Top Honors From the Cancer Research Institute for Outstanding Contributions to Cancer Immunology and Immunotherapy on September 10, 2018 at 2:50 pm
Newswise — NEW YORK, September 10, 2018—The Cancer Research Institute (CRI), a nonprofit organization dedicated to the discovery and development of immunotherapies for all forms of cancer, will bestow ... […]
- Often-overlooked Natural Killer cells may be key to cancer immunotherapy on September 10, 2018 at 1:17 pm
Immune checkpoint inhibitors are revolutionizing the treatment of cancer, but new research challenges the central dogma of how these drugs work. This research shows for the first time that often-overl... […]
via Google News and Bing News